Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | CTSD | P07339 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17238160 | 1.00 | PSENEN (0.53) | PSENENCTSSCTSKCTSDALDH1A1 | |
| SCHEMBL22636430 | 1.00 | PSENEN (0.53) | PSENENCTSSCTSKCTSDALDH1A1 | |
| SCHEMBL1057086 | 0.87 | CTSS (0.54) | PSENENCTSSCTSKALDH1A1CA2 | |
| SCHEMBL16667727 | 0.87 | KLK5 (0.50) | PSENENCTSSCTSKCTSDKLK5 | |
| SCHEMBL25652880 | 0.87 | KLK5 (0.50) | PSENENCTSSCTSKCTSDKLK5 | |
| SCHEMBL18181474 | 0.86 | KLK5 (0.42) | PSENENCTSSCTSKCTSDALDH1A1 | |
| SCHEMBL5576894 | 0.86 | KLK5 (0.44) | PSENENCTSSCTSKALDH1A1KLK5 | |
| SCHEMBL2255391 | 0.86 | KLK5 (0.44) | PSENENCTSSCTSKALDH1A1KLK5 | |
| SCHEMBL1486223 | 0.85 | PSENEN (0.62) | PSENENCTSSCTSKCTSDCA2 | |
| SCHEMBL1486221 | 0.85 | PSENEN (0.62) | PSENENCTSSCTSKCTSDCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114585637-B | MASP-inhibitory compounds and uses thereof | 拜耳公司 | 2025-04-15 | — | — | CN | disclosed |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-06 | — | — | US | disclosed |
| CN-114585637-A | MASP inhibiting compounds and uses thereof | 拜耳公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20210246166-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2021-08-12 | — | — | US | disclosed |
| WO-2020225095-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-12 | — | — | WO | disclosed |
| EP-3252045-B1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | ABBVIE INC (US) | 2019-09-04 | — | — | EP | disclosed |
| US-10112911-B2 | Substituted cyanoguanidines as oral anti-virals | ABBVIE INC. (US) | 2018-10-30 | — | — | US | disclosed |
| EP-2867221-B1 | CYANOGUANIDINES AND THEIR SUE AS ANTIVIRAL AGENTS. | ABBVIE INC (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-3252045-A1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | AbbVie Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20150322045-A1 | CYANOGUANIDINES AND USES THEREOF | ABBVIE INC. | 2015-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322045-A1 | CYANOGUANIDINES AND USES THEREOF | GMPS, RNGTT, RNMT | PSENEN 4771/4885CTSS 1844/4885CTSK 2781/4885 |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | PSENEN 2530/4885CTSS 138/4885CTSK 149/4885 |
| US-10112911-B2 | Substituted cyanoguanidines as oral anti-virals | RNGTT, GMPS, RNMT | PSENEN 4710/4885CTSS 2103/4885CTSK 2940/4885 |
| US-20210246166-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | PSENEN 2530/4885CTSS 138/4885CTSK 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.